E. Jacquet

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer

C. Friedenreich, D. Cox, F. Penault-Llorca, 2020, Scientific Reports.

Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer

B. Allenet, P. Bedouch, M. Mousseau, 2016, Targeted Oncology.

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

J. Blay, N. Albin, L. Boudali, 2022, International journal of cancer.

Added therapeutic benefit regarding ESMO-MCBS and French health technology assessment of drugs granted early access program.

J. Blay, E. Jacquet, F. Y. Pham, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?

A. Seigneurin, P. Delafosse, E. Jacquet, 2022, Breast Cancer Research.

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.

N. Albin, L. Boudali, F. Grudé, 2021, European journal of cancer.

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.

B. Pistilli, L. Vanlemmens, A. Guizard, 2018, European journal of cancer.

Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013

J. Timsit, D. Moro-Sibilot, S. Ruckly, 2021, BMC Cancer.

Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey

B. Fervers, F. Reyal, L. Delrieu, 2021, Cancers.

Aberrant activation of five embryonic stem cell-specific genes robustly predicts a high risk of relapse in breast cancers

Florent Chuffart, S. Khochbin, S. Rousseaux, 2023, BMC Genomics.